Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of SPD465 in Adults With ADHD
NCT00152035Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2005
- Primary completion
- Nov 2006
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of SHP465 mixed amphetamine salts in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Primary endpoint: Safety Evaluation at 20 months. Started Mar 2005; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00152035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152035.